Patterns of Lapses and Recoveries During a Quit Attempt Using Varenicline and Behavioral Counseling
Friday, August 14, 2020
Posted by: Natalia Gromov
Ashare RL, Wileyto EP,
Logue-Chamberlain E, et al.
Patterns of Lapses and
Recoveries During a Quit Attempt Using Varenicline and Behavioral Counseling
Among Smokers With and Without HIV.
[published online ahead of print, 2020 Jul 20]. Psychol Addict Behav.
2020;10.1037/adb0000619. doi:10.1037/adb0000619
Addressing tobacco use among HIV+ smokers is a priority. Lack of knowledge
about how HIV+ smokers respond to tobacco use treatments limits our ability to
effectively treat this population of smokers. Using data from 2 clinical trials
that provided 12 weeks of varenicline and behavioral counseling, 1 with smokers
with HIV (n = 89) and 1 with smokers without HIV (n = 179), we used mixed
logistic regression modeling to compare point-prevalence abstinence rates and
adherence to the initial target quit date (TQD) and Cox regression for repeated
outcomes to evaluate lapse and recovery dynamics between the groups. Sixty
percent of HIV- smokers refrained from smoking at the TQD while only 33% of
HIV+ smokers did (odds ratio [OR] = 0.32, 95% CI [0.18, 0.56], p < .001).
The point-prevalence abstinence rates at Week 12 were 31% (HIV-) and 28% (HIV+;
OR = 0.7, 95% CI [0.42, 1.16], p = .16) and the point prevalence abstinence
rates at Week 24 were 22% (HIV-) and 15% (HIV+; OR = 0.87, 95% CI [0.49, 1.57],
p = .65). Although there was no interaction between HIV status and lapse risk,
χ2(3) < 1, there was a significant interaction for the recovery model,
(χ2(3) = 20.4, p < 0.001): as the number of events increased, the time to
the next recovery became longer among smokers with HIV, compared to smokers
without HIV. Although HIV+ smokers were treated effectively with varenicline,
compared to HIV- smokers, they showed significantly lower initial cessation at
the TQD and took increasingly longer to recover following lapses. (PsycInfo
Database Record (c) 2020 APA, all rights reserved).
|
|
Email to a Friend